* If you want to update the article please login/register
Rheumatoid arthritis is a chronic systemic autoimmune disease that is characterized by synovial inflammation and autoimmunity. The main cause of the disease is a lack of pro-inflammatory macrophages and anti-inflammatory macrophages in the joint's synovial tissues. To restore this balance, the interleukin-10 encoding anti-inflammatory cytokines and chemotherapeutic drug dexamethasone sodium phosphate were co-loaded into human serum albumin-preparing pDNA/DSP-NPs to specifically target macrophages in synovium tissue to promote M1-M2 polarization. The accumulation of nanoparticles in the inflammatory joint site was higher than that of In vivo, the real-time fluorescence imaging system and HPLC, was used to investigate nanoparticle delivery and pharmacokinetics, but the results revealed that the accumulation of nanoparticles in the inflammatory joint site was higher. To promote macrophage polarization in M1-M2 cells, the synergistic treatment effect of IL-10 pDNA and DSP in this system was achieved by lowering the presence of pro-inflammatory genes and raising the expression of anti-inflammatory factors.
Source link: https://europepmc.org/article/MED/35363114
This research resulted in the creation of novel silk fibroin hydrogel containing Sesbania sesban L. extract, a plant with high anti-inflammatory properties that are helpful for rheumatoid arthritis therapy. Using appropriate techniques, the gel properties of morphology, gelation time, viscosity, gel strength, stability, drug loading capability, drug delivery rate, and in-vitro anti-inflammatory activity were investigated. The optimal formulation had a strong porous structure, with a gelation time of 0. 5 h at room temperature and bodily temperature of 37 ° C, a gel thickness of 2530 g, and a physical stability of > 6 months. Moreover, the hydrogel contained the Sesbania sesban L. leaf extract with a total phenolic content of 92. 8 mg/g, and maintained the release rate for > 20 d. u1ea1ys, according to the Hichi model.
Source link: https://europepmc.org/article/MED/35277106
To prevent arthritis progression, Germacrone can control the T helper 1 cell/the T helper 2 cell ratio. To reverse M1-type proinflammatory cells and reduce inflammation, FA receptor-targeted nanocarriers loaded with GER were developed. FA-NPs/GER could induce the transformation of M1 macrophages into M2 macrophages, according to in vitro studies. Pro-inflammatory cytokines in the rat's inflammatory tissue were significantly lower than those in other therapy groups, indicating a significant therapeutic effect in AIA rats.
Source link: https://europepmc.org/article/MED/35225122
The dextran sulfate was modified as the target molecular by binding to the macrophage's scavenger receptor. The MMP-2 inflammatory peptide was used to crack in the inflammatory microenvironment to accelerate the release of Cel in the in vitro release study. DPC@Cel had better anti-rheumatoid arthritis benefits and lower systemic toxicity than free Cels, according to In vivo experiments.
Source link: https://europepmc.org/article/MED/35119317
Objectives The present study sought to determine the likelihood of osteoporotic fracture in patients of Rheumatoid arthritis by Fracture Risk Assessment Tool and its association with osteoporotic-specific risk factors. In addition, we reviewed the FRAX algorithm for all patients and controls to determine the 10-year fracture risk of major osteoporotic fracture and hip fractures. The results showed a significant positive correlation between two fractures in patients with significant onset of disease, previous fracture, and a 10-year risk of hip fracture. Conclusions as determined by the FRAX device, the risk of hip fracture and major osteoporotic fracture in both male and female patients with RA also increased significantly. A significant association between major osteoporotic fracture and hip fracture appeared during the disease's duration, previous fracture, and parent fracture hip fractures.
Source link: https://europepmc.org/article/MED/35057596
Rheumatoid arthritis is a chronic autoimmune disorder. Traditional ethnic medicine has particular strengths in the treatment of such disorders. The aim of this research was to clarify the therapeutic effects of different polar ginsenosides on RA and to investigate the metabolic profiles of ginsenosides in a collagen-induced arthritis model using untargeted metabolomics based on ultra-performance liquid chromatography-mass spectrometry. With respect to catecholamine biosynthesis and vitamin B6 metabolism, polar ginsenosides modified urine metabolomics. This research has shown that less-polar ginsenosides can relieve inflammatory symptoms to a greater extent than polar ginsenosides.
Source link: https://europepmc.org/article/MED/IND607716317
Rheumatoid arthritis suffers severe joint and bone damage due to an increased immune response at the articular sites. RA has a three-fold incidence and prevalence rate in the worldwide population of 36,000 people and 1% respectively, as well as 1%. Here, we have extensive data on the treatment of RA, as well as studies evaluating various combinations of trials. According to our systematic review of current research, conventional DMARDs as well as glucocorticoid may be the most appropriate for early RA patients, and a combination of conventional and targeted DMARDs may be most appropriate for treating seronegative patients with moderate to high RA activity. However, certain adverse events connected with the current therapy have hampered with the current therapy's continued success, such as gene therapy and mesenchymal stem cell transplantation.
Source link: https://europepmc.org/article/MED/35725992
Objects: To describe the feature of expression of syndecan-4 in serum, synovial fluid, and synovium in rheumatoid arthritis patients, and to investigate the relationship between syndecan-4 with disease activity and serological characteristic of RA. In RA patients, the relationship between serum syndecan-4 concentration and disease severity was found. Results The serum syndedcan-4 concentration in RA patients and healthy controls was much higher in RA patients than in OA patients and healthy controls, and it was even higher in rheumatoid factor-positive RA patients than in RF-negative ones. In a SF of RA patients, the Syndecan-4 concentration was similar to OA patients. The expression of Syndecan-4 antibodies in synovial tissue was similar between RA and OA patients. Conclusion The serum syndecan-4 concentration in RA patients was higher in RA patients than in OA patients, and it was significantly higher in RF-positive RA patients than in RF-negative ones. Both serum and SF were positively correlated with disease risk in RA patients, according to Syndecan-4 concentration.
Source link: https://europepmc.org/article/MED/35725524
Objects : Objectives: Several hypotheses have existed for the explanation of placebo response rates in randomised controlled trials of patients with rheumatoid arthritis with IR to methotrexate. We pooled placebo patients from both trials and compared the American College of Rheumatology (20%/70%) response rates and the Clinical Disease Activity Index low disease activity between those receiving placebo and those receiving placebo without any background disease modifying antirheumatic drugs — along with an estimated baseline illness. ACR20 responses were generated by 72%85 of placebo-continued MTX and 14/113 of placebo-only patients, respectively; for ACR50, they were 25/285 versus 0/113, and for ACR70 they were 8/285 versus 0/113. In addition, more patients with placebo-continued MTX had CDAI-LDA at week 16 than with placebo-only compared to placebo only. Conclusions Patients who are still receiving ineffective MTX background therapy have higher responses to placebo.
Source link: https://europepmc.org/article/MED/35725294
Objectives: To find clusters of comorbidities in patients with rheumatoid arthritis using four methods and compare patients without RA. Methods In this retrospective, population-based review, residents of 8 Minnesota counties with prevalent RA on 1-1-2015 were identified. Using two codes u226530 days apart, 44 previously identified morbidities and 11 non-overlapping chronic disease groups based on Clinical Classifications Software were identified. Results Two groups of 1643 patients with and without RA were tested. Clusters that employ various random seeds or bootstrap sampling impugns the usefulness and reliability of these techniques's effectiveness. Across RA and non-RA cohorts, clusters of common comorbidities were similar. Conclusion Conclusion: Despite the higher comorbidity burden in patients with RA compared to the general population, clustering comorbidities in RA and non-RA cohorts did not reveal significant differences in comorbidity patterns between the RA and non-RA cohorts. Clustering results using one method may cause caution when interpreting clustering using one method.
Source link: https://europepmc.org/article/MED/35724274
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions